Sun Pharmaceutical Industries
sun-pharma
No plans to get into vaccine production as it requires separate manufacturing infra: Sun Pharma
Commenting on the company's Halol plant, which has been under the USFDA radar for the last few years, Shanghvi said the drug firm is waiting for the regulator to inspect the facility.
Infosys, Mahindra & Mahindra, Sun Pharma, Eicher Motors, IPCA Lab, UCO Bank stocks in focus
Nifty futures were trading 51.50 points or 0.33 per cent higher at 15,465.50 on Singaporean Exchange in early trade on Friday.
Sun Pharma Q4 net profit zooms over twofold to Rs 894.15 crore
The company had posted a net profit of Rs 399.84 crore in the corresponding period of the previous fiscal, Sun Pharma said in a regulatory filing.
Eicher Motors, Sun Pharma, Cadila, TCS, BPCL, Burger King, Pfizer, PNB Housing stocks in focus
Nifty futures were trading flat at 15,305 in early trade on Singaporean Exchange, suggesting a cautious opening for BSE Sensex and Nifty 50 on Thursday.
Nifty may hit 15,000, if it holds 14,700; Bank Nifty looks positive on charts; buy TCS, Wipro, among others
The chart pattern suggests that if Nifty 50 index crosses and sustains above 14,700 level it would witness buying which would lead the index towards 14,900-15,000 levels.
Sun Pharma, Jindal Steel among top stocks to buy, sell; intraday chart suggests Nifty may fall up to 14,130
The Nifty / Sensex hovering in the range of 14600 to 14400/ 47500-49000 price range and the texture of the pattern suggest narrow range activity likely to continue in the near future.
Stocks to buy: HDFC Bank, HCL Tech look strong on charts; Nifty may hit 15,050 if Bank Nifty performs well
On a weekly chart, the market has managed to regain the levels of 14750, which is positive in the short term that would help the market to move beyond 14900 levels.
Stocks in focus today: HDFC, RIL, L&T, JSPL, Sun Pharma, Yes Bank, Adani Enterprises, Jubilant FoodWorks
After rising for the nine consecutive sessions, BSE Sensex and Nifty 50 look to open in the negative territory on Tuesday, as suggested by the trends on SGX Nifty in early trade.
Sun Pharma, ICGEB to develop botanical drug for dengue
Sun Pharmaceutical Industries today signed a pact with International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a novel botanical drug for treatment of dengue.
Sun Pharma recalls 3.8 lakh cartons of osteoporosis drug in US
The drug has some presence of ‘unknown impurity’, which was manufactured at the company’s Halol facility in Gujarat Around 3.8 lakh cartons of an osteoporosis drug manufactured by Sun Pharmaceutical Industri
Sun completes sale of two Ranbaxy divisions to Strides Shasun
The agreement involved transfer of these two marketing divisions, along with employees to Strides, for Rs 165 crore Sun Pharmaceutical Industries has completed the process of selling two divisions of erstwhile Ranbaxy Laborat
Sun Pharma raises Rs 1,000 crore via NCDs
NCDs will be listed on BSE under two series Sun Pharmaceutical Industries has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. “Sun Pharma Laboratories, a wholly-ow
Sun Pharma receives warning letter for Halol facility
The company expects a re-inspection by US FDA Sun Pharmaceutical Industries has received a warning letter from the US FDA as a result of the September 2014 inspection, for its facility located at Halol, Gujarat. Sun Pharma re
Sun Pharma in collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies
Adopts novel approach towards development of a treatment for glioblastoma, a lethal form of brain cancer Sun Pharmaceutical Industries has entered into a tripartite research and option agreement with Israel-based Weizmann Ins
Sun Pharma receives US FDA approval for Gleevec
These tablets are indicated for the treatment of chronic myeloid leukemia
Sell rating on Sun Pharma; A quarter miss on revenues
Sun Pharma's base business fell due to customer consolidation and competitive pressures
Sun Pharma Q2 net profit down 46% at Rs 1,107 crore
Drug major Sun Pharmaceutical Industries today reported 46.02 per cent dip in its consolidated net profit at Rs 1,106.66 crore for the second quarter...
Sun Pharma acquires InSite Vision
The acquisition was completed by means of a short-form merger under Delaware law Sun Pharmaceutical Industries has acquired InSite Vision Incorporated. The acquisition was completed by means of a short-form merger under Delaw
Sun Pharma seeks shareholders’ nod on Rs 50K cr provision
Sun Pharmaceutical is seeking approval of its shareholders through a postal ballot earmarking of up to Rs 50,000 crore for the purpose of acquisitions or providing loans, among others.
Sun Pharma announces Absorica patent litigation settlement
Ranbaxy Pharmaceuticals along with its partners, Cipher Pharmaceuticals and Galephar Pharmaceutical Research have entered into a settlement agreement with Actavis Group Sun Pharmaceutical Industries announced that Ranbaxy Pha
Sun Pharma commences tender offer for acquisition of InSite Vision
The tender offer will expire on October 27, 2015, at 12:00 midnight New York City time Sun Pharmaceutical Industries has commenced a tender offer through its indirect wholly-owned subsidiary, Thea Acquisition Corporation, for
Retain OW on Sun Pharma, target Rs 1,010: Morgan Stanley
Sun Pharma has announced the acquisition of Insite Vision US for $48 million in equity value (net debt of US$3.5 million in Dec ember 2014).
Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
The agreement involves transfer of Ranbaxy’s Solus and Solus Care divisions, along with employees to Strides for a consideration of Rs 1,650 million Sun Pharmaceutical Industries and Strides Arcolab have entered into a defi
Sun Pharma to acquire US-based InSite Vision
Sun Pharmaceutical Industries has entered into an agreement with InSite Vision to acquire the US-based eyecare firm for around $48 million plus related debt and other transaction costs to strengthen its branded ophthalmic por
Sun Pharma to acquire InSite Vision
Strengthens branded ophthalmic portfolio in US Sun Pharmaceutical Industries’ subsidiary has entered into an agreement and plan of merger with InSite Vision, under which a Sun Pharma subsidiary has offered to acquire In
Sun Pharma in race to acquire InSite Vision?
Drug major Sun Pharmaceutical Industries is said to be in race to acquire US-based eye care firm InSite Vision Inc at a price of $0.35 per share.
Sun Pharma looking to divest Ireland plant
Sun Pharmaceutical Industries Ltd said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.
